Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Rating of “Moderate Buy” by Analysts

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $7.25.

A number of research firms have recently weighed in on MIST. Wall Street Zen cut shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Raymond James Financial began coverage on shares of Milestone Pharmaceuticals in a research note on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price target on the stock. Zacks Research cut shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, May 15th. Finally, Wells Fargo & Company lowered their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th.

Milestone Pharmaceuticals Stock Up 1.6%

Milestone Pharmaceuticals stock opened at $1.31 on Friday. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.18 and a quick ratio of 9.09. Milestone Pharmaceuticals has a 1-year low of $1.00 and a 1-year high of $3.06. The company has a market cap of $163.10 million, a PE ratio of -1.93 and a beta of 0.95. The stock’s 50 day moving average price is $1.64 and its 200 day moving average price is $1.81.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.12 million. On average, sell-side analysts predict that Milestone Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Insiders Place Their Bets

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 36,500 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $2.26, for a total value of $82,490.00. Following the sale, the chief executive officer owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.03% of the company’s stock.

Institutional Trading of Milestone Pharmaceuticals

Large investors have recently bought and sold shares of the company. Strategic Family Wealth Counselors L.L.C. acquired a new stake in Milestone Pharmaceuticals in the fourth quarter valued at $25,000. Eaton Financial Holdings Company LLC acquired a new stake in Milestone Pharmaceuticals in the fourth quarter valued at $26,000. Welch & Forbes LLC acquired a new stake in Milestone Pharmaceuticals in the first quarter valued at $30,000. Bank of America Corp DE grew its holdings in Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after purchasing an additional 16,044 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new stake in Milestone Pharmaceuticals in the fourth quarter valued at $42,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.